Connect with us

Technology

Frost & Sullivan grants the Global Medical Imaging Foundation Model Innovation Award to Hangzhou Diagens Biotechnology Co.,Ltd.

Published

2 years ago

on

SHANGHAI, Sept. 18, 2024 /PRNewswire/ — Frost & Sullivan is pleased to announce that the 18th Growth Innovation Leadership (GIL) Summit and the 3rd New Investment Event (NIE 2024), was held in Shanghai from August 27 to 30, 2024, co-hosted by LeadLeo.

Based on the research and analysis of the global medical imaging foundation model in recent years, as well as the study and evaluation of related companies in the industry, Frost & Sullivan has awarded Hangzhou Diagens Biotechnology Co.,Ltd. the Global Medical Imaging Foundation Model Innovation Award at the GIL Summit and NIE 2024. Mr. Aroop Zutshi, the Global Managing Partner and Executive Board Member of Frost & Sullivan, and Professor Yu Wang, the Chairman of Chinese Foundation for Hepatitis Prevention and Control and the Former Director General of Chinese Center for Disease Control and Prevention presented this award to Mr. Chengfa Wu, the secretary to the board of Hangzhou Diagens Biotechnology Co.,Ltd.

Diagens independently developed the world’s leading generalized medical imaging model, and its achievements have been widely recognized

Hangzhou Diagens Biotechnology Co.,Ltd. (“Diagens”) was founded in 2016, focusing on the core technology innovation of artificial intelligence in medical imaging. The company has independently developed the world’s leading generalized medical imaging model and has made significant achievements in the field of artificial intelligence medical imaging.

As China’s national-level specialized and innovative “Little Giant” enterprise, national technology-based enterprise, and national high-tech enterprise, Diagens has more than 60 core intellectual property rights in China, the United States and Europe, and its scientific and technological achievements have been widely recognized. Among them, the core products of Diagens’s artificial intelligence model for medical imaging have obtained 27 certificates from NMPA in China, CE in the EU and FDA in the US, and won the first prize in the Science and Technology Achievement Award of the China Birth Defects Intervention and Relief Foundation, as well as ranked the first in reproductive field in the “Artificial Intelligence Medical Devices” list of the China’s Ministry of Industry and Information Technology.

Diagens’s core technology catches up with overseas, setting a new benchmark for the industry

Relying on its deep technical accumulation and excellent innovation ability in the field of medical imaging, Diagens has successfully developed a large model on the medical imaging foundation, which has been applied to karyotype analysis. The system combines the core technology of AI imaging with precision optical equipment, and its world’s first third-generation karyotype analysis technology sets up a new benchmark of accuracy and efficiency in the industry. Through this innovative application, the industry’s accuracy benchmark has been raised from 50% to 99.45%, and the time for issuing clinical reports has been shortened from nearly 30 days to only 4 days, significantly improving the efficiency.

This breakthrough achievement of Diagens has established a new paradigm for global karyotype analysis and has obtained the International First-of-its-kind Equipment Certification. In addition, the technology has been evaluated by the China’s national expert group as an international leader in core technology, and the products have been sold to more than 400 China’s Grade A tertiary hospitals, providing strong support for clinical diagnosis and treatment.

Diagens continues to enhance its technological capabilities for the global medical imaging market

The medical imaging foundation large model of Diagens has now been successfully applied to the comprehensive solution of cytogenetic laboratory, which includes fully autonomous, whole process and fully intelligent cytogenetic diagnostic services, such as high-efficiency cultivation, automatic acquisition, automatic preparation, intelligent scanning, intelligent analysis, and online diagnosis. The solution is applicable to many fields such as prenatal diagnosis, assisted reproduction, hematology and oncology, radiation medicine and radiation safety.

In the future, Diagens will continue to increase the number of self-developed large models. Targeting the global medical imaging market worth hundreds of billions of dollars, Diagens plans to spend another 3-5 years achieving comprehensive technological leadership in various medical imaging sub-sectors. Through continuous innovation and breakthroughs, Diagens will be committed to providing more efficient and accurate diagnostic tools for patients and healthcare workers, and promoting the sustainable development of the medical imaging field.

About Frost & Sullivan’s Global Leadership Award

The Frost & Sullivan Global Leadership Award recognizes enterprises’ outstanding performance and exceptional achievements in areas such as technology innovation, market potential, customer service, branding, and others. The Frost & Sullivan team nominated a group of competitive and excellent enterprises through methods including in-depth interviews, industry analysis, and secondary research. An independent judging panel, made up of third-party investment and financing experts, financial experts, bankers, and renowned listed company entrepreneurs, conducted rigorous evaluations of the nominated enterprises and decided to grant the Global Medical Imaging Foundation Model Innovation Award to Hangzhou Diagens Biotechnology Co.,Ltd.

View original content:https://www.prnewswire.com/apac/news-releases/frost–sullivan-grants-the-global-medical-imaging-foundation-model-innovation-award-to-hangzhou-diagens-biotechnology-coltd-302251612.html

SOURCE Frost & Sullivan

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Department of Health – Abu Dhabi and Fred Hutchinson Cancer Center collaborate on cancer research and personalized prevention

Published

6 hours ago

on

May 13, 2026

By

ABU DHABI, UAE, May 13, 2026 /PRNewswire/ — The Department of Health – Abu Dhabi (DoH), regulator of the healthcare sector in the emirate, together with the Abu Dhabi Public Health Center (ADPHC), today announced the execution of a Memorandum of Understanding (“MOU”) with Fred Hutchinson Cancer Center (Fred Hutch), one of the world’s leading cancer research institutions and home to three Nobel laureates.

By pairing Abu Dhabi’s unified clinical and genomic data infrastructure, sovereign AI capabilities and governed data environments with Fred Hutch’s globally renowned research engine, the ensuing collaborations will pave the way to shortening the distance between scientific discovery and patient benefit, for Abu Dhabi’s community and beyond.

Among the projected collaborations, the two organizations will consider leveraging Abu Dhabi’s intelligent health system, and layering Fred Hutch’s world-class science onto the secure, high-quality, real-world data foundation Abu Dhabi has built. That foundation includes the emirate’s pioneering liquid biopsy programme launched last year, one of the first national-scale efforts of its kind anywhere in the world. Alongside Abu Dhabi’s AI multi-cancer early detection work, and the world’s largest clinically integrated population-scale genomics programme – with nearly one million genomes sequence.

During his visit to the center, HE Mansoor Ibrahim Al Mansoori, Chairman of DoH commented: “Cancer is one of the defining health challenges of our time, and progress depends on combining world-class science with population-scale data, advanced AI, and research. In Abu Dhabi, we have built an AI-enabled health system that ‘cares before it cures, delivering prevention at population scale. We are already achieving some of the highest early cancer detection rates in the world, and through our partnership with Fred Hutchinson Cancer Center we are committed to bringing breakthroughs to people in Abu Dhabi and beyond.”

“This MOU between Fred Hutch Cancer Center and the Abu Dhabi Department of Health underscores the power of working together to prevent and treat cancer,” said Thomas Lynch Jr., MD, president and director of Fred Hutch and holder of the Raisbeck Endowed Chair. “Our organizations share a deep commitment to research and to provide the highest levels of cancer prevention, diagnosis and care to our communities, and we are excited to bring our expertise, tools and datasets together to identify unique approaches to cancer care and research in pursuit of our boldest goals.”

Photo – https://mma.prnewswire.com/media/2979204/DoH_Abu_Dhabi.jpg
Logo- https://mma.prnewswire.com/media/2714371/5968536/DoH_Logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/department-of-health—abu-dhabi-and-fred-hutchinson-cancer-center-collaborate-on-cancer-research-and-personalized-prevention-302770894.html

SOURCE The Department of Health – Abu Dhabi

Continue Reading

Technology

L’Mychele & Associates Founder LaKessia Hill Completes North Texas FWC Hospitality Program (FIFA World Cup) and Appears on The Jeff Crilley Show

Published

6 hours ago

on

May 13, 2026

By

DALLAS, May 13, 2026 /PRNewswire/ — L’Mychele & Associates LLC is proud to announce two significant milestones for the growing strategic meetings and events firm: Founder & CEO LaKessia Hill has successfully completed the North Texas FWC Organizing Committee’s Hospitality Program and was recently featured on The Jeff Crilley Show.

These accomplishments reflect the company’s continued momentum within the hospitality, tourism, and events industries as L’Mychele & Associates expands its presence through strategic partnerships, leadership engagement, and elevated client experiences.

The completion of the North Texas FWC Hospitality Program further strengthens the company’s commitment to delivering intentional, guest-centered experiences rooted in strategy, hospitality, and meaningful connection — values that are central to the L’Mychele & Associates brand.

In addition, Hill recently joined veteran journalist and media personality Jeff Crilley on The Jeff Crilley Show to discuss her entrepreneurial journey, the vision behind L’Mychele & Associates, and the company’s approach to creating experiences as bold as its clients’ goals.

“Both opportunities represent growth, visibility, and the continued evolution of our brand,” said Hill. “Hospitality is more than service — it’s about creating intentional moments that leave lasting impressions. Being recognized through the hospitality program and having the opportunity to share our story on The Jeff Crilley Show were both incredibly meaningful experiences.”

Known for its consultative and strategy-first approach, L’Mychele & Associates specializes in executive summits, conferences, nonprofit galas, incentive experiences, corporate meetings, and curated social gatherings. The firm partners with organizations, brands, and leaders to transform ideas into impactful experiences through strategic planning, management, and execution.

Guided by the company’s signature philosophy — “The Art of Listening. The Science of Execution.” — L’Mychele & Associates continues to position itself as a strategic partner within the meetings, events, and hospitality industries.

The episode of The Jeff Crilley Show featuring LaKessia Hill is now available across multiple platforms, including YouTube, Facebook, LinkedIn, and Transistor.

About L’Mychele & Associates LLC

L’Mychele & Associates LLC is a Dallas-based strategic meetings and events firm specializing in executive summits, corporate meetings, conferences, nonprofit events, incentive experiences, and curated social gatherings. The company is known for blending strategy, hospitality, and execution to create experiences that drive connection and lasting impact.

Media Contact

LaKessia Hill
Founder & CEO, L’Mychele & Associates LLC
469-402-7825

LaKessia@LMychele.com
www.LMychele.com  

View original content to download multimedia:https://www.prnewswire.com/news-releases/lmychele–associates-founder-lakessia-hill-completes-north-texas-fwc-hospitality-program-fifa-world-cup-and-appears-on-the-jeff-crilley-show-302770319.html

SOURCE L’Mychele & Associates LLC

Continue Reading

Technology

HBX GROUP ANNOUNCES HALF YEAR 2026 FINANCIAL RESULTS

Published

6 hours ago

on

May 13, 2026

By

LONDON, May 13, 2026 /PRNewswire/ — HBX Group International plc (HBX Group, the Company, the Group, HBX.SM) announces its Half Year 2026 results for the six months ended 31 March 2026.  

TTV up +17% to €3.8bn, and Revenue of €309m, up +1% YoY at constant currency, reflecting targeted commercial and strategic actions to prioritise growth and capture market share, partly offset by disruption from the Middle East conflictAdjusted EBITDA up +9% at constant currency to €163m, with margin of 53% expanding +4ppts in constant currency. Profit after tax was €28m (H1 25: €(227)m).Strong cash generation with 103% cash conversion and leverage at 1.7x Adjusted Net Debt / Adjusted EBITDA. S €100m share buyback programme and a 7.5 cents per share (c.€18m) interim dividend.Executing the strategic building blocks, including the acquisition of Bridgify announced today.FY26E guidance revised to reflect the impact of Middle East conflict and macroeconomic uncertainty. New FY26 guidance is for constant currency TTV growth +11% to +15%, Revenue growth -4% to +1% and Adjusted EBITDA growth -5% to -2%, and Operating Free Cash Flow conversion between 90% and 100%. Medium-term guidance is unchanged.

First half 2026 Financial Performance Summary1

6 months
ended 31
March 2026

6 months
ended 31
March 2025

Change
constant
currency2

Change 

Total Transaction Value (TTV) (€m)

3,770

3,370

+17 %

+12 %

Revenue (€m)

309

319

+1 %

-3 %

Adjusted EBITDA (€m)

163

159

+9 %

+3 %

Delivering profitable growth

Group TTV increased to €3.8bn in the first half, up +17% at constant currency. TTV contribution increased from shorter lead-time bookings, Third Party Supply and Online Travel Agents.

Revenue of €309m, increased +1% in constant currency. Take rate was 8.2%, down 1.3ppts year‑on‑year.

Adjusted EBITDA increased 9%, with margin +4ppts.

Net finance costs were €35m, 77% lower than the prior year. The tax charge was €16m. Adjusted Earnings were €83m, up +44% at constant currency.

Delivering commercial milestones in line with strategy

Commercial progress in H1 2026 reflected HBX Group’s strategy to expand its global travel ecosystem and drive profitability through AI-driven operational efficiency and commercial performance. Key developments included new distribution partnerships in Asia-Pacific, acquisitions such as Bridgify and PerfectStay to strengthen experiences and dynamic capabilities, and new platform and fintech initiatives.

HBX group also continued embedding AI across products and operations, including AI-powered solutions for Bedsonline and HotelTech, while scaling internal AI agents already delivering measurable savings and supporting more than 120 identified use cases, reinforcing the Group’s connected B2B travel ecosystem strategy.

Regional performance and trading dynamics

TTV grew in double-digits in all three regions, up +18% in the Americas and +16% in both MEAPAC and Europe, at constant currency.

In Europe, TTV growth was supported by strong intra‑regional and domestic travel. Asia Pacific up +18%, partly offset by slower growth in the Middle East and disruption on some Europe-Asia corridors. In the Americas, TTV was predominantly driven by domestic demand.

Middle East impact and near‑term outlook

Since late February, the escalation of the conflict in the Middle East has impacted travel demand across affected destinations and selected international corridors, resulting in increased volatility, shorter booking windows and reduced near‑term visibility. The impact of this on H1 Group TTV growth was approximately 1ppt.

HBX Group implemented dynamic pricing, inventory reallocation and active partner support. Demand outside affected corridors has been more resilient.

Cost discipline, cash generation and capital allocation

Underlying operating costs fell by 5%. Performance was supported by productivity initiatives, automation and AI.

On a last 12-month basis, Operating Free Cash Flow was €447m, with cash conversion of 103% over the last 12 months. Adjusted Net Debt at 31 March 2026 stood at €741m.

Outlook

The Group started FY26 with strong performance. Since late February, trading conditions have been adversely impacted by the escalation of the conflict in the Middle East and broader geopolitical uncertainty.

The Group has revised its FY26 guidance. Updated outlook reflects a -4ppt effect of the Middle East conflict on TTV growth. Assumes four months of disruption with gradual stabilisation.

For the complete press release and disclaimer applicable to this information, please visit www.investors.hbxgroup.com

1 See financial statements for definitions of specific financial terms and KPIs, including any Alternative Performance Measures (APMs)
2 Constant currency changes exclude the impact of foreign exchange rate fluctuations by translating current year results at the exchange rates used in the prior year.

Contact: 
Clara Truyols
clatruyols@hbxgroup.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/hbx-group-announces-half-year-2026-financial-results-302770897.html

SOURCE HBX Group

Continue Reading

Trending